Efsubaglutide Alfa

依苏帕格鲁肽α

Report date: 2026/04/09 20:00:21

Base Information

Drug NameEfsubaglutide Alfa
Drug Alias Name依苏帕格鲁肽αSupaglutide苏帕鲁肽Efsubaglutide达必刚 +[12] 
ClassificationBiologics > Protein drugs > Recombinant polypeptideBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsOverweightObesityDiabetes Mellitus, Type 2 +[4] 
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryMainland China
Original Approved Date2025/01/24
Country/TerritoryUnited StatesAustraliaBrazil +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGuangzhou Yinnuo Pharmaceutical Group Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGuangzhou Yinnuo Pharmaceutical Group Co LtdShanghai Yinnuo Pharmaceutical Technology Co Ltd
Inactive CompaniesIntellective Suzhou Co Ltd
Active IndicationsOverweightObesityDiabetes Mellitus, Type 2 +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeA10BJ
Related LinksWikipedia